Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction

American Journal of Gastroenterology

Volumn 107, Issue 3, 2012, Pages 389-396

  Ng, Fook Hong ^a   Tunggal, P ^a   Chu, Wai Ming ^a   Lam, Kwok Fai ^b   Li, Andrew ^a   Chan, Kit ^a   Lau, Yuk Kong ^a   Kng, Carolyn ^a   Keung, K K ^a   Kwan, Ambrose ^a   Wong, Benjamin C Y ^b  

^a RUTTONJEE HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; ESOMEPRAZOLE; FAMOTIDINE; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EROSION; FEMALE; FOLLOW UP; GASTROINTESTINAL OBSTRUCTION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ULCER; UPPER GASTROINTESTINAL BLEEDING;

ACUTE CORONARY SYNDROME; AGED; ANTI-ULCER AGENTS; ASPIRIN; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENOXAPARIN; FAMOTIDINE; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTESTINAL PERFORATION; MALE; MIDDLE AGED; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84857910372     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.385     Document Type: Article

References (38)

1. Anderson JL, Adams CD, Antman EM et al. AHA 2007 Guidelines for the management of patients with unstable angina/non-ST elevation myocardial infarction a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007; 116: e148-304.
2. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010; 105: 2533-49.
3. Yeomans N, Lanas A, Labenz J et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103: 2465-73.
4. Taha AS, Hudson N, Hawkey CJ et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435-9. (Pubitemid 26157439)
5. Taha AS, McCloskey C, Prasad R et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 119-25.
6. Bhatt DL, Cryer B, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-17.
7. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST ? elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2004; 110: e82-e292.
8. Khasawneh SM, Affarah HB. Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing. Am J Gastroenterol 1992; 87: 1180-2.
9. Yin Q, Chow SS, Tomlinson B. Clinical Bioequivalence Study on Two Famotidine Formulations (Famolta vs Pepcidine). 28 p. The Chinese University of Hong Kong, 2003.03.15.
10. Ng FH, Wong SY, Lam KF et al. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel and enoxaparin in acute coronary syndrome. Am J Gastroenterol 2008; 103: 865-71.
11. Ng FH, Lam KF, Wong SY et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion 2008; 77: 173-7.
12. O ' Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56. (Pubitemid 10242750)
13. Chin MW, Yong G, Bulsara MK et al. Predictive and protective factors asso ciated with upper gastrointestinal bleeding aft er percutaneous coronary intervention: a case ? control study. Am J Gastroenterol 2007; 102: 2411-6. (Pubitemid 47631776)
14. Luinstra M, Naunton M, Peterson GM et al. PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation. J Clin Pharm Ther 2010; 35: 213-7.
15. Barada K, Karrowni W, Abdallah M et al. Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors. J Clin Gastro 2008; 42: 368-72. (Pubitemid 351450621)
16. Hsu PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology 2011; 140: 791-8.
17. Sung JJ, Lau JY, Ching JY et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152: 1-9.
18. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008; 51: 256-60.
19. US FDA (17 November 2009), Follow-up to the January 26, 2009, Early Communication about an Ongoing Safety Review of Clopidogrel Bisulfate and Omeprazole.
20. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. JACC 2008; 52: 1038-9.
21. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-8.
22. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
23. Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010; 170: 704-10.
24. Gaglia MA Jr, Torguson R, Hanna N et al. Relation of proton pump inhibitor use aft er percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol 2010; 105: 833-8.
25. van Boxel OS, van Oijen MG, Hagenaars MP et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010; 105: 2430-6.
26. Kreutz RP, Stanek EJ, Aubert R et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel aft er coronary stent placement: the clopidogrel MEDCO outcomes study. Pharmacotherapy 2010; 30: 787-96.
27. Tsai YW, Wen YW, Huang WF et al. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus protonpump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol 2011; 46: 39-45.
28. Dunn SP, Macaulay TE, Brennan DM et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008; 118: S815.
29. Rassen JA, Choudhry NK, Avorn J et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors aft er percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-9.
30. O ' Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton pump inhibitor: an analysis of two randomized trials. Lancet 2009; 374: 989-97.
31. Ray WA, Murray KT, Griffin MR et al. Outcomes with concurrent use of clopidogrel and proton pump inhibitors. Ann Intern Med 2010; 152: 337-45.
32. Cappell MS. The safety and clinical utility of esophagogastroduodenoscopy for acute gastrointestinal bleeding aft er myocardial infarction: a six-year study of 42 endoscopies in 34 consecutive patients at two university teaching hospitals. Am J Gastroenterol 1993; 88: 344-50. (Pubitemid 23085839)
33. Lee JG, Krucoff MW, Brazer SR. Periprocedural myocardial ischemia in patients with severe symptomatic coronary artery disease undergoing endoscopy: prevalence and risk factors. Am J Med 1995; 99: 270-5.
34. Cappell MS, Iacovone FM Jr. Safety and efficacy of esophagogastroduodenoscopy aft er myocardial infarction. Am J Med 1999; 106: 29-35. (Pubitemid 29077139)
35. Eikelboom JW, Mehta SR, Anand SS et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-82. (Pubitemid 44268228)
36. Nikolsky E, Stone GW, Kirtane AJ et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 54: 1293-302.
37. Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. N Engl J Med 1990; 323: 1672-80.
38. Wilder-Smith C, Backlund A, Eckerwall G et al. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. Clin Drug Investig 2008; 28: 333-43 . (Pubitemid 351685390)